333 related articles for article (PubMed ID: 30720184)
1. Activated YAP causes renal damage of type 2 diabetic nephropathy.
Ma R; Ren JM; Li P; Zhou YJ; Zhou MK; Hu Z; Xiao XY
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):755-763. PubMed ID: 30720184
[TBL] [Abstract][Full Text] [Related]
2. Targeting mammalian serine/threonine-protein kinase 4 through Yes-associated protein/TEA domain transcription factor-mediated epithelial-mesenchymal transition ameliorates diabetic nephropathy orchestrated renal fibrosis.
Yang T; Heng C; Zhou Y; Hu Y; Chen S; Wang H; Yang H; Jiang Z; Qian S; Wang Y; Wang J; Zhu X; Du L; Yin X; Lu Q
Metabolism; 2020 Jul; 108():154258. PubMed ID: 32376130
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of transcriptional coactivator YAP Impairs the expression and function of transcription factor WT1 in diabetic podocyte injury.
Chen J; Wang X; He Q; Yang HC; Fogo AB; Harris RC
Kidney Int; 2024 Jun; 105(6):1200-1211. PubMed ID: 38423183
[TBL] [Abstract][Full Text] [Related]
4. Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β-Catenin Expression and Podocyte Epithelial-Mesenchymal Transition.
Dai HY; Ma LN; Cao Y; Chen XL; Shi H; Fan YP; Yang B
J Cell Biochem; 2017 Nov; 118(11):3706-3712. PubMed ID: 28370212
[TBL] [Abstract][Full Text] [Related]
5. RhoA protects the podocytes against high glucose-induced apoptosis through YAP and plays critical role in diabetic nephropathy.
Huang Z; Peng Y; Yu H; Yu X; Zhou J; Xiao J
Biochem Biophys Res Commun; 2018 Oct; 504(4):949-956. PubMed ID: 30220545
[TBL] [Abstract][Full Text] [Related]
6. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
[TBL] [Abstract][Full Text] [Related]
7. YAP-mediated mechanotransduction determines the podocyte's response to damage.
Rinschen MM; Grahammer F; Hoppe AK; Kohli P; Hagmann H; Kretz O; Bertsch S; Höhne M; Göbel H; Bartram MP; Gandhirajan RK; Krüger M; Brinkkoetter PT; Huber TB; Kann M; Wickström SA; Benzing T; Schermer B
Sci Signal; 2017 Apr; 10(474):. PubMed ID: 28400537
[TBL] [Abstract][Full Text] [Related]
8. IL-17 and CD40 ligand synergistically stimulate the chronicity of diabetic nephropathy.
Kuo HL; Huang CC; Lin TY; Lin CY
Nephrol Dial Transplant; 2018 Feb; 33(2):248-256. PubMed ID: 28339909
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-26a inhibits TGF-β-induced extracellular matrix protein expression in podocytes by targeting CTGF and is downregulated in diabetic nephropathy.
Koga K; Yokoi H; Mori K; Kasahara M; Kuwabara T; Imamaki H; Ishii A; Mori KP; Kato Y; Ohno S; Toda N; Saleem MA; Sugawara A; Nakao K; Yanagita M; Mukoyama M
Diabetologia; 2015 Sep; 58(9):2169-80. PubMed ID: 26063197
[TBL] [Abstract][Full Text] [Related]
10. Correlation between serum carnosinase concentration and renal damage in diabetic nephropathy patients.
Zhou Z; Liu XQ; Zhang SQ; Qi XM; Zhang Q; Yard B; Wu YG
Amino Acids; 2021 May; 53(5):687-700. PubMed ID: 33811534
[TBL] [Abstract][Full Text] [Related]
11. Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice.
Roestenberg P; van Nieuwenhoven FA; Joles JA; Trischberger C; Martens PP; Oliver N; Aten J; Höppener JW; Goldschmeding R
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1344-54. PubMed ID: 16380465
[TBL] [Abstract][Full Text] [Related]
12. Glomerular expression of CTGF, TGF-beta 1 and type IV collagen in diabetic nephropathy.
Umezono T; Toyoda M; Kato M; Miyauchi M; Kimura M; Maruyama M; Honma M; Yagame M; Suzuki D
J Nephrol; 2006; 19(6):751-7. PubMed ID: 17173248
[TBL] [Abstract][Full Text] [Related]
13. Correlation of CTGF gene promoter methylation with CTGF expression in type 2 diabetes mellitus with or without nephropathy.
Zhang H; Cai X; Yi B; Huang J; Wang J; Sun J
Mol Med Rep; 2014 Jun; 9(6):2138-44. PubMed ID: 24676352
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of miR-30c promotes renal fibrosis by target CTGF in diabetic nephropathy.
Wang J; Duan L; Guo T; Gao Y; Tian L; Liu J; Wang S; Yang J
J Diabetes Complications; 2016 Apr; 30(3):406-14. PubMed ID: 26775556
[TBL] [Abstract][Full Text] [Related]
15. Interaction of the EGF Receptor and the Hippo Pathway in the Diabetic Kidney.
Chen J; Harris RC
J Am Soc Nephrol; 2016 Jun; 27(6):1689-700. PubMed ID: 26453611
[TBL] [Abstract][Full Text] [Related]
16. Urinary mRNA markers of epithelial-mesenchymal transition correlate with progression of diabetic nephropathy.
Zheng M; Lv LL; Cao YH; Zhang JD; Wu M; Ma KL; Phillips AO; Liu BC
Clin Endocrinol (Oxf); 2012 May; 76(5):657-64. PubMed ID: 21824169
[TBL] [Abstract][Full Text] [Related]
17. Glomerular expression of platelet-derived growth factor (PDGF)-A, -B chain and PDGF receptor-alpha, -beta in human diabetic nephropathy.
Uehara G; Suzuki D; Toyoda M; Umezono T; Sakai H
Clin Exp Nephrol; 2004 Mar; 8(1):36-42. PubMed ID: 15067514
[TBL] [Abstract][Full Text] [Related]
18. Expression of Endothelial Cell Injury Marker Cd146 Correlates with Disease Severity and Predicts the Renal Outcomes in Patients with Diabetic Nephropathy.
Fan Y; Fei Y; Zheng L; Wang J; Xiao W; Wen J; Xu Y; Wang Y; He L; Guan J; Wei J; He JC; Wang N
Cell Physiol Biochem; 2018; 48(1):63-74. PubMed ID: 30001528
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic value of lipoprotein-associated phospholipase A2 in early diabetic nephropathy.
Zhai Y; Cao X; Liu S; Shen Y
Ann Med; 2023; 55(2):2230446. PubMed ID: 37566692
[TBL] [Abstract][Full Text] [Related]
20. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes.
Guha M; Xu ZG; Tung D; Lanting L; Natarajan R
FASEB J; 2007 Oct; 21(12):3355-68. PubMed ID: 17554073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
